Cost-Effectiveness of First-Line Nivolumab Plus Ipilimumab Combination Therapy in Advanced Non-Small-Cell Lung Cancer in Japan

被引：0
|
作者：
Xiuting Mo
Kensuke Moriwaki
Kosuke Morimoto
Kojiro Shimozuma
机构：
[1] Ritsumeikan University,Comprehensive Unit for Health Economic Evidence Review and Decision Support (CHEERS), Research Organization of Science and Technology
[2] Kyoto University,Graduate School of Medicine
[3] Ritsumeikan University,Division of Health Services Research, Department of Biomedical Sciences, College of Life Sciences
[4] Ritsumeikan University,Comprehensive Unit for Health Economic Evidence Review and Decision Support (CHEERS), Research Organization of Science and Technology
来源：
Clinical Drug Investigation | 2022年 / 42卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：599 / 609
页数：10
相关论文
共 50 条
  • [1] Cost-Effectiveness of First-Line Nivolumab Plus Ipilimumab Combination Therapy in Advanced Non-Small-Cell Lung Cancer in Japan
    Mo, Xiuting
    Moriwaki, Kensuke
    Morimoto, Kosuke
    Shimozuma, Kojiro
    CLINICAL DRUG INVESTIGATION, 2022, 42 (07) : 599 - 609
  • [2] Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non-small-cell Lung Cancer
    Hao, Xuezhi
    Shen, Aizong
    Wu, Bin
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [3] Cost-effectiveness of nivolumab plus ipilimumab versus chemotherapy as first-line therapy in advanced non-small cell lung cancer
    Shu, Yamin
    Ding, Yiling
    Li, Feie
    Zhang, Qilin
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 114
  • [4] Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer
    Wan, Xiaomin
    Zeng, Xiaohui
    Peng, Liubao
    Peng, Ye
    Liu, Qiao
    Yi, Lidan
    Luo, Xia
    Deng, Qijian
    Tan, Chongqing
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [5] Cost-effectiveness Analysis of Nivolumab Plus Ipilimumab Combination Therapy as First-line Treatment for Advanced Renal Cell Carcinoma in Japan
    Maeda, Tomomi
    Moriwaki, Kensuke
    Morimoto, Kosuke
    Yoshioka, Takashi
    Goto, Rei
    Shimozuma, Kojiro
    VALUE IN HEALTH REGIONAL ISSUES, 2024, 40 : 118 - 126
  • [6] Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
    Hu, Huabin
    She, Longjiang
    Liao, Mengting
    Shi, Yin
    Yao, Linli
    Ding, Dong
    Zhu, Youwen
    Zeng, Shan
    Carbone, David P.
    Huang, Jin
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [7] Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
    Wu, Bin
    Zhang, Qiang
    Sun, Jie
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [8] Cost-Effectiveness of Nivolumab Plus Ipilimumab Combined with Two Cycles of Chemotherapy as First-Line Treatment in Advanced Non-Small Cell Lung Cancer
    Peng, Ye
    Zeng, Xiaohui
    Peng, Liubao
    Liu, Qiao
    Yi, Lidan
    Luo, Xia
    Li, Sini
    Wang, Liting
    Qin, Shuxia
    Wan, Xiaomin
    Tan, Chongqing
    ADVANCES IN THERAPY, 2021, 38 (07) : 3962 - 3972
  • [9] Cost-Effectiveness of Nivolumab Plus Ipilimumab Combined with Two Cycles of Chemotherapy as First-Line Treatment in Advanced Non-Small Cell Lung Cancer
    Ye Peng
    Xiaohui Zeng
    Liubao Peng
    Qiao Liu
    Lidan Yi
    Xia Luo
    Sini Li
    Liting Wang
    Shuxia Qin
    Xiaomin Wan
    Chongqing Tan
    Advances in Therapy, 2021, 38 : 3962 - 3972
  • [10] Cost effectiveness of combination ipilimumab-nivolumab in advanced non-small-cell lung cancer.
    Courtney, Patrick T.
    Yip, Anthony T.
    Cherry, Daniel R.
    Salans, Mia A.
    Kumar, Abhishek
    Murphy, James Don
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345